UA105029C2 - ПОДВІЙНЕ НАЦІЛЮВАННЯ НА miR-208 І miR-499 У ЛІКУВАННІ ЗАХВОРЮВАНЬ СЕРЦЯ - Google Patents
ПОДВІЙНЕ НАЦІЛЮВАННЯ НА miR-208 І miR-499 У ЛІКУВАННІ ЗАХВОРЮВАНЬ СЕРЦЯInfo
- Publication number
- UA105029C2 UA105029C2 UAA201110646A UAA201110646A UA105029C2 UA 105029 C2 UA105029 C2 UA 105029C2 UA A201110646 A UAA201110646 A UA A201110646A UA A201110646 A UAA201110646 A UA A201110646A UA 105029 C2 UA105029 C2 UA 105029C2
- Authority
- UA
- Ukraine
- Prior art keywords
- mir
- subject
- cardiac disorders
- treatment
- dual targeting
- Prior art date
Links
- 108091092539 MiR-208 Proteins 0.000 title abstract 3
- 108091056170 miR-499 stem-loop Proteins 0.000 title abstract 3
- 108091050885 miR-499-1 stem-loop Proteins 0.000 title abstract 3
- 108091038523 miR-499-2 stem-loop Proteins 0.000 title abstract 3
- 208000020446 Cardiac disease Diseases 0.000 title abstract 2
- 208000019622 heart disease Diseases 0.000 title abstract 2
- 230000009977 dual effect Effects 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 208000023178 Musculoskeletal disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002064 heart cell Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 108091070501 miRNA Proteins 0.000 abstract 1
- 239000002679 microRNA Substances 0.000 abstract 1
- 210000002363 skeletal muscle cell Anatomy 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Analytical Chemistry (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14991509P | 2009-02-04 | 2009-02-04 | |
| PCT/US2010/023234 WO2010091204A1 (en) | 2009-02-04 | 2010-02-04 | Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA105029C2 true UA105029C2 (uk) | 2014-04-10 |
Family
ID=42542383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201110646A UA105029C2 (uk) | 2009-02-04 | 2010-02-04 | ПОДВІЙНЕ НАЦІЛЮВАННЯ НА miR-208 І miR-499 У ЛІКУВАННІ ЗАХВОРЮВАНЬ СЕРЦЯ |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8629119B2 (enExample) |
| EP (1) | EP2393945A4 (enExample) |
| JP (1) | JP5943608B2 (enExample) |
| KR (1) | KR20110128838A (enExample) |
| CN (1) | CN102356162A (enExample) |
| AU (1) | AU2010210605B2 (enExample) |
| BR (1) | BRPI1008517A2 (enExample) |
| CA (1) | CA2751489A1 (enExample) |
| MX (1) | MX2011008190A (enExample) |
| NZ (1) | NZ594365A (enExample) |
| RU (1) | RU2515926C2 (enExample) |
| UA (1) | UA105029C2 (enExample) |
| WO (1) | WO2010091204A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5995855B2 (ja) * | 2010-11-05 | 2016-09-21 | ミラゲン セラピューティクス，インコーポレイテッド | 塩基修飾オリゴヌクレオチド |
| WO2012083004A2 (en) * | 2010-12-15 | 2012-06-21 | Miragen Therapeutics | Blood-borne mirnas as surrogate markers of drug efficacy for cardiac conditions |
| CA2817371A1 (en) * | 2010-12-15 | 2012-06-21 | Miragen Therapeutics | Microrna inhibitors comprising locked nucleotides |
| US9428749B2 (en) | 2011-10-06 | 2016-08-30 | The Board Of Regents, The University Of Texas System | Control of whole body energy homeostasis by microRNA regulation |
| EP2584040A1 (en) | 2011-10-17 | 2013-04-24 | Pharmahungary 2000 Kft. | Compounds for treatment of ischemic injury |
| CN104685056A (zh) * | 2012-06-21 | 2015-06-03 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| CN102980920A (zh) * | 2012-11-14 | 2013-03-20 | 华东师范大学 | 同时检测miRNAs与蛋白标记物的硅纳米线芯片及其检测方法和应用 |
| CN105154445B (zh) * | 2014-06-12 | 2018-07-27 | 中国科学院上海生命科学研究院 | 新的肌营养不良肌病的血清miRNA标志物 |
| WO2016022536A2 (en) * | 2014-08-04 | 2016-02-11 | MiRagen Therapeutics, Inc. | Inhibitors of myh7b and uses thereof |
| HK1249108A1 (zh) | 2015-01-20 | 2018-10-26 | 米拉根医疗股份有限公司 | Mir-92抑制剂及其用途 |
| PT3283508T (pt) | 2015-04-17 | 2021-06-21 | Alpine Immune Sciences Inc | Proteínas imuno modulatórias com afinidades afináveis |
| KR20190118688A (ko) * | 2015-06-05 | 2019-10-18 | 미라젠 세러퓨틱스 인코포레이티드 | 피부 t 세포 림프종(ctcl) 치료용 mir-155 억제제 |
| CA3198255A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| WO2019136179A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN108815535B (zh) * | 2018-08-08 | 2020-05-19 | 哈尔滨医科大学 | 一种抗心肌肌钙蛋白抗体修饰并载有miR-21的脂质体及其制备方法和应用 |
| CN119246849B (zh) * | 2024-12-09 | 2025-03-14 | 上海基灵生物科技有限公司 | 一种检测犬心脏损伤的试剂盒及应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004522411A (ja) | 2000-07-31 | 2004-07-29 | ジーン ロジック インコーポレイテッド | 分子毒性学モデリング |
| RU2311921C2 (ru) * | 2000-09-13 | 2007-12-10 | Чугаи Сейяку Кабусики Кайся | Лекарственные средства для лечения ишемических заболеваний |
| CZ20031569A3 (cs) * | 2000-12-07 | 2003-11-12 | Gencell S. A. | Polynukleotidy obsahující fragment sekvence v protisměru od genu CARP, vektory a expresní kazety, které je obsahují, a jejich použití |
| US20050124568A1 (en) | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA) |
| US6964950B2 (en) * | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
| IL161100A0 (en) | 2001-09-28 | 2004-08-31 | Max Planck Gesellschaft | Identification of novel genes coding for small temporal rnas |
| WO2003065993A2 (en) | 2002-02-04 | 2003-08-14 | Gene Logic, Inc. | Primary rat hepatocyte toxicity modeling |
| US20080214437A1 (en) | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US7781415B2 (en) | 2003-02-07 | 2010-08-24 | Roche Madison Inc. | Process for delivering sirna to cardiac muscle tissue |
| EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| WO2005047505A2 (en) | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro rnas |
| WO2005017145A1 (ja) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法 |
| US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
| EP2295604B1 (en) | 2004-02-09 | 2015-04-08 | Thomas Jefferson University | Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features |
| AU2005214904B2 (en) | 2004-02-13 | 2011-07-21 | Rockefeller University | Anti-microRNA oligonucleotide molecules |
| AU2005250432B2 (en) | 2004-05-28 | 2011-09-15 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US7635563B2 (en) | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
| WO2006013561A2 (en) | 2004-08-02 | 2006-02-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for diagnosing and treating post traumatic stress disorder |
| JP2006101790A (ja) | 2004-10-06 | 2006-04-20 | Japan Health Science Foundation | 高血圧症のリスクの評価方法 |
| WO2006047454A2 (en) | 2004-10-21 | 2006-05-04 | Rutgers, The State University Of New Jersey | Rational probe optimization for detection of micrornas |
| CA2857881A1 (en) | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| WO2006063356A1 (en) | 2004-12-10 | 2006-06-15 | Isis Phamaceuticals, Inc. | Regulation of epigenetic control of gene expression |
| US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| EP1959012A3 (en) | 2004-12-29 | 2009-12-30 | Exiqon A/S | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs |
| US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| US9085774B2 (en) | 2005-04-19 | 2015-07-21 | Basf Plant Science Gmbh | Methods controlling gene expression |
| SI2002003T1 (sl) | 2005-05-27 | 2016-05-31 | Ospedale San Raffaele S.R.L. | Genski vektor, ki vsebuje mi-RNA |
| US20070077582A1 (en) | 2005-09-16 | 2007-04-05 | Primera Biosystems, Inc. | Method for quantitative detection of short RNA molecules |
| US20070092882A1 (en) | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| AU2006326517B2 (en) | 2005-12-12 | 2013-02-21 | The University Of North Carolina At Chapel Hill | MicroRNAs that regulate muscle cell proliferation and differentiation |
| EP1966390A1 (en) | 2005-12-29 | 2008-09-10 | Exiqon A/S | Detection of tissue origin of cancer |
| JP5213723B2 (ja) | 2006-01-27 | 2013-06-19 | アイシス ファーマシューティカルズ， インコーポレーテッド | マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物 |
| MX2008012219A (es) | 2006-04-03 | 2008-10-02 | Santaris Pharma As | Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn. |
| KR101485495B1 (ko) * | 2006-08-01 | 2015-01-22 | 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 베타-마이오신 중사슬의 발현을 활성화하는 마이크로-ｒｎａ의 동정 |
| US20090306181A1 (en) | 2006-09-29 | 2009-12-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| US8906870B2 (en) | 2006-10-09 | 2014-12-09 | Julius-Maximilians-Universitaet Wuerzberg | MicroRNA (miRNA) for the diagnosis and treatment of heart diseases |
| CA2681568C (en) | 2006-11-23 | 2019-01-08 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
| EA200900782A1 (ru) * | 2006-12-14 | 2009-12-30 | Новартис Аг | Композиции и способы, предназначенные для лечения мышечных и сердечно-сосудистых нарушений |
| EP3536788A1 (en) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Microrna target site blocking oligos and uses thereof |
| WO2008074328A2 (en) | 2006-12-21 | 2008-06-26 | Exiqon A/S | Microrna target site blocking oligos and uses thereof |
| WO2008147837A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds, non-naturally occurring micro-rnas, and methods for optimizing non-naturally occurring micro-rnas |
| CN101808649B (zh) | 2007-07-31 | 2014-05-21 | 得克萨斯系统大学董事会 | 控制肌球蛋白表达和肌纤维身份的微小rna |
| US20100292099A1 (en) | 2007-08-23 | 2010-11-18 | Keren Pharmaceutical, Inc. | Targeting of rna with external guide sequences |
| AU2008306327B2 (en) | 2007-10-04 | 2014-05-15 | Roche Innovation Center Copenhagen A/S | Micromirs |
| WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| JP5654352B2 (ja) | 2007-11-09 | 2015-01-14 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | ｍｉＲ−１５ファミリーのマイクロＲＮＡによる心筋細胞生存及び心臓修復の調節 |
| WO2009114681A2 (en) | 2008-03-13 | 2009-09-17 | Dharmacon, Inc. | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy |
| US20090326049A1 (en) | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
| EP2297322A1 (en) | 2008-06-04 | 2011-03-23 | The Board of Regents of The University of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
| EP2303292A4 (en) | 2008-06-09 | 2013-01-02 | New York Medical College | COMPOSITIONS WITH CARDIAL STEM CELLS WITH OVEREXPRESSION OF SPECIFIC MICRORNAS AND METHOD FOR THEIR USE IN THE REPAIR OF THE CARED MYOCARDIC |
| US8987435B2 (en) | 2008-10-24 | 2015-03-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
-
2010
- 2010-02-04 CA CA 2751489 patent/CA2751489A1/en not_active Abandoned
- 2010-02-04 NZ NZ59436510A patent/NZ594365A/xx not_active IP Right Cessation
- 2010-02-04 BR BRPI1008517A patent/BRPI1008517A2/pt not_active IP Right Cessation
- 2010-02-04 KR KR20117020396A patent/KR20110128838A/ko not_active Ceased
- 2010-02-04 US US13/147,784 patent/US8629119B2/en not_active Expired - Fee Related
- 2010-02-04 CN CN2010800123730A patent/CN102356162A/zh active Pending
- 2010-02-04 EP EP20100739137 patent/EP2393945A4/en not_active Withdrawn
- 2010-02-04 JP JP2011548431A patent/JP5943608B2/ja not_active Expired - Fee Related
- 2010-02-04 RU RU2011136640/10A patent/RU2515926C2/ru not_active IP Right Cessation
- 2010-02-04 MX MX2011008190A patent/MX2011008190A/es active IP Right Grant
- 2010-02-04 AU AU2010210605A patent/AU2010210605B2/en not_active Ceased
- 2010-02-04 WO PCT/US2010/023234 patent/WO2010091204A1/en not_active Ceased
- 2010-02-04 UA UAA201110646A patent/UA105029C2/uk unknown
-
2013
- 2013-12-12 US US14/104,886 patent/US20140179764A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN102356162A (zh) | 2012-02-15 |
| WO2010091204A1 (en) | 2010-08-12 |
| EP2393945A1 (en) | 2011-12-14 |
| JP2012516856A (ja) | 2012-07-26 |
| NZ594365A (en) | 2013-03-28 |
| EP2393945A4 (en) | 2013-08-07 |
| RU2011136640A (ru) | 2013-03-10 |
| MX2011008190A (es) | 2011-10-06 |
| AU2010210605B2 (en) | 2015-08-13 |
| US20140179764A1 (en) | 2014-06-26 |
| BRPI1008517A2 (pt) | 2016-03-08 |
| KR20110128838A (ko) | 2011-11-30 |
| AU2010210605A1 (en) | 2011-08-25 |
| US8629119B2 (en) | 2014-01-14 |
| CA2751489A1 (en) | 2010-08-12 |
| JP5943608B2 (ja) | 2016-07-05 |
| US20120035243A1 (en) | 2012-02-09 |
| RU2515926C2 (ru) | 2014-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA105029C2 (uk) | ПОДВІЙНЕ НАЦІЛЮВАННЯ НА miR-208 І miR-499 У ЛІКУВАННІ ЗАХВОРЮВАНЬ СЕРЦЯ | |
| WO2012020307A3 (en) | Therapeutic uses of microvesicles and related micrornas | |
| MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
| PH12013500919B1 (en) | Vasoprotective and cardioprotective antidiabetic therapy | |
| PH12017501500A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
| MX2019005130A (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente. | |
| EP2294184A4 (en) | TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY | |
| WO2011038210A3 (en) | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity | |
| MX2011009751A (es) | Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2. | |
| HK1245677A1 (zh) | 用於治疗炎症和癌症的杂环itk抑制剂 | |
| WO2009048932A3 (en) | Methods to regulate mirna processing by targeting lin-28 | |
| WO2012024478A3 (en) | Treatment of nicotinamide phosphoribosyltransferase (nampt) related diseases by inhibition of natural antisense transcript to nampt | |
| PH12014502698A1 (en) | Improved antagonist antibodies against gdf-8 and uses therefor | |
| WO2009045356A3 (en) | Microrna compositions in the treatment of vegf-mediated disorders | |
| MX2011008221A (es) | Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno. | |
| MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
| EP2755721A4 (en) | A SYSTEM AND METHOD FOR THE TREATMENT OF THE SKIN AND ANIMAL WEAVE FOR IMPROVED HEALTH, FUNCTION AND / OR IMPROVED APPEARANCE | |
| WO2011123745A3 (en) | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 | |
| PH12013501688A1 (en) | Treatment of amyotrophic lateral sclerosis using umbilical derived cells | |
| WO2011103528A3 (en) | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 | |
| WO2011091390A3 (en) | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 | |
| WO2011143640A3 (en) | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 | |
| WO2012038504A3 (en) | Breast cancer therapeutics | |
| HK1197276A1 (en) | Methods and compositions for the treatment and diagnosis of bladder cancer | |
| WO2012009402A3 (en) | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |